Discover investment opportunities in List Of Healthcare Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Healthcare Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Healthcare Stocks using our Smart AI Filter.
9 stocks found for "List Of Healthcare Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.49 | ±19.6% | 26.1 | 1.76% | |||
0.36 | ±21.7% | 15.1 | 3.17% | |||
0.77 | ±40.2% | 10.4 | 3.94% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.64 | ±28.2% | 69.3 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How have historical performances of Johnson & Johnson (JNJ) impacted its investment appeal during economic downturns?
A: Johnson & Johnson (JNJ) has historically been viewed as a defensive stock due to its diversified business model across consumer health, pharmaceuticals, and medical devices. This diversification often provides stability in economic downturns, as its broad product range can buffer sector-specific downturns.
Q: What is the income potential of Pfizer (PFE) for dividend-focused investors?
A: Pfizer (PFE) offers an attractive dividend yield, with a history of stable and consistent dividend payments. Investors focused on income should assess the sustainability of these dividends by reviewing Pfizer's financial health and payout ratio.
Q: What sector-specific opportunities does Merck (MRK) present in the biotech industry?
A: Merck (MRK) is prominent in the biotech industry, particularly through its research and development in oncology and vaccines. Its innovative pipeline and recent successful drug launches may present growth opportunities, attracting investors interested in biotech advancements.
Q: How does Abbott Laboratories (ABBV) perform in terms of growth potential compared to peers?
A: Abbott Laboratories (ABBV) has shown strong growth potential, attributable to its successful pharmaceutical products like Humira. However, the expiration of patents poses challenges, making it vital for investors to watch for diversification and new product developments.
Q: What are the risks of investing in Thermo Fisher Scientific (TMO) given its current market valuation?
A: Thermo Fisher Scientific (TMO) trades at relatively high valuation multiples compared to peers, reflecting growth expectations. Risks include market overvaluation and potential volatility due to any underperformance in expected revenue growth.
Q: What are the competitive advantages of Amgen (AMGN) in the pharmaceutical sector?
A: Amgen's (AMGN) competitive advantage lies in its established biotech drug portfolio and robust R&D pipeline. Its focus on biologics and biosimilars offers a strategic edge in developing and marketing high-margin drugs, appealing to growth-focused investors.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read more